SuperworthBridgeBio Pharma market cap BBIO
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Oct 23, 2026
- $13.4B
- Highest close in our data
- $16.8B
- Jul 2026
BridgeBio Pharma is worth $13.4B at the close on Oct 23, 2026, at $68.56 a share.
That is up 29% over the last year and up 81% over five years.
Its highest close in our data was $16.8B in Jul 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $13.4B | $12.7B | $16.8B | −8% |
| 2025 | $14.6B | $5.3B | $14.7B | +176% |
| 2024 | $5.3B | $4.4B | $6.7B | −25% |
| 2023 | $7B | $1.1B | $7.1B | +517% |
| 2022 | $1.1B | $977.7M | $2.2B | −54% |
| 2021 | $2.5B | $2.5B | $10.6B | −72% |
| 2020 | $8.7B | $2.8B | $8.7B | +91% |
| 2019 | $4.6B | $2.1B | $5.1B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest BridgeBio Pharma's size, closest first, today.
| Company | Market cap |
|---|---|
| BBIOBridgeBio Pharma | $13.4B |
| JAZZJazz Pharmaceuticals | $13.9B |
| BMRNBiomarin Pharmaceutical | $10.8B |
| CORTCorcept Therapeutics | $9.3B |
| PTGXProtagonist Therapeutics | $9B |
| TGTXTG Therapeutics | $8.3B |
| ALKSAlkermes plc. | $7.3B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| LGNDLigand Pharmaceuticals | $6.1B |
| KNSAKiniksa Pharmaceuticals International | $6B |
| BIIBBiogen | $37B |
| Peer median | $8.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on BridgeBio Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.